TRIPASS XR تري باس

 

Immunoglobulins

Data regarding the use of immunoglobulins as adjunctive therapy for the treatment of

select infections in the neutropenic cancer patient are primarily limited to case

reports. Patients with pneumonia secondary to CMV may benefit from adjunctive

immunoglobulin therapy (in combination with ganciclovir). In addition, IV

immunoglobulin G should be considered in those patients with

hypogammaglobulinemia.

G-CSF administration, although likely to reduce the duration of her chemotherapyinduced neutropenia, is not indicated in S.B., who is otherwise stable.

KEY REFERENCES AND WEBSITES

A full list of references for this chapter can be found at

http://thepoint.lww.com/AT11e. Below are the key references and websites for this

chapter, with the corresponding reference number in this chapter found in parentheses

after the reference.

Key References

Averbuch D et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era

of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Haematologica. 2013;98:1826–1835. (176)

Flowers CR et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated

for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–

810. (32)

Lehrnbecher T et al. Guideline for the management of fever and neutropenia in children with cancer and/or

undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–4438. (177)

National Comprehensive Cancer Network. Myeloid growth factors (version 1.2015). www.nccn.org. Accessed

September 4, 2015. (84)

Network Comprehensive Cancer Network. Prevention and treatment of cancer-related infections (v2.2015).

www.nccn.org. Accessed September 3, 2015. (3)

Smith TJ et al. Recommendations for the use of white blood cell growth factors: American Society of Clinical

Oncology Clinical Practice Guideline Update. J Oncol Pract. 2015. (83)

Key Websites

National Comprehensive Cancer Network. www.nccn.org.

American Society of Clinical Oncology. www.asco.org.

COMPLETE REFERENCES CHAPTER 75 PREVENTION

AND TREATMENT OF INFECTIONS IN NEUTROPENIC

PATIENTS

Bodey GP. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and

neutropenia: the early years. J Antimicrob Chemother. 2009;63(Suppl 1):i3–13.

de Naurois J et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol.

2010;21(Suppl 5):v252–v256.

Network Comprehensive Cancer Network. Prevention and treatment of cancer-related infections (v2.2015).

www.nccn.org. Accessed September 3, 2015.

Freifeld A et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer:

2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–431.

Bodey G. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Ann Intern Med. 1966;64:328–332.

Schimpff SC et al. Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. J Infect

Dis. 1974;130(Suppl):S24–S31.

Boogaerts M et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical

antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum

antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412–422.

Gomes DM et al. Comparison of acute kidney injury during treatment with vancomycin in combination with

piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34:662–669.

Tomblyn M et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation

recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–1238.

Crawford J et al. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann

Oncol. 2010;21:248–251.

Stuck AE et al. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis.

1989;11:954–963.

Zanfi C et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation:

rejection and infection rates in 40 recipients during the early postoperative period. Transplant Proc. 2010;42:35–

38.

Park SH et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell

transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis. 2009;11:413–423.

Marti FM et al. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol. 2009;20(Suppl

4):166–169.

Hughes WT et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin

Infect Dis. 2002;34:730–751.

Barton TD, Schuster MG. The cause of fever following resolution of neutropenia in patients with acute leukemia.

Clin Infect Dis. 1996;22:1064–1068.

Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in

patients with cancer and neutropenia. Clin Infect Dis. 2005;40(Suppl 4):S246–S252.

Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the

currently isolated pathogens. Clin Infect Dis. 2004;39:S25–S31.

Cordonnier C et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a

more targeted antibiotic strategy. Clin Infect Dis. 2003;36:149–158.

Mathur P et al. A study of bacteremia in febrile neutropenic patients at a tertiary-care hospital with special

reference to anaerobes. Med Oncol. 2002;19:267–272.

Bollee G et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305–

1310.

Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N EnglJ Med. 2004;350:2487–2498.

Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis. 2004;39:S38–

S43.

Bohme A et al. Treatment of invasive fungal infections in cancer patients—recommendations of the Infectious

Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann

Hematol. 2009;88:97–110.

Bennett JEP. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic

patients. Clin Infect Dis. 2003;36:S117–S122.

Hagen EA et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin

Infect Dis. 2003;36:9–15.

Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol. 2002;81:233–243.

Ninin E et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow

transplants. Clin Infect Dis. 2001;33:41–47.

Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of

America. Clin Infect Dis. 2008;46:327–360.

Hahn-Ast C et al. Overallsurvival and fungal infection-related mortality in patients with invasive fungal infection

and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob

Chemother. 2010;65:761–768.

Aapro MS et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce

the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders

and solid tumours. Eur J Cancer. 2011;47(1):8–32.

Flowers CR et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated

for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794–

810.

Klastersky J et al. The Multinational Association for Supportive Care in Cancer risk index: a multinationalscoring

system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–3051.

Feld R et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated

guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer,

with emphasis on outpatient studies. Clin Infect Dis. 2002;35:1463–1468.

Schimpff SC et al. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse

isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med. 1975;82:351–358.

Young GA et al. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients

with leukaemia. Antifungal Prophylaxis Study Group. Eur J Cancer. 1999;35:1208–1213.

Owens NJ et al. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med. 1984;144:290–293.

Akiyama H et al. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced

neutropenic patients with haematological malignancies. Mycoses. 1993;36:373–378.

Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of

invasive fungal infections. Int J Antimicrob Agents. 2006;27(Suppl 1):36–44.

Rijnders BJ et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis

during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46:1401–1408.

Maertens J et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell

transplant recipients:summary of the ECIL 3—2009 Update. Bone Marrow Transplant. 2011;46(5):709–718.

Gotzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in

patients with cancer. Cochrane Database Syst Rev. 2002;(9):CD000026.

Bodey GP et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus

intravenous amphotericin B. Cancer. 1994;73:2099–2106.

Mattiuzzi GN et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as

prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous

leukemia and myelodysplastic syndrome. Cancer. 2003;97:450–456.

Nucci M et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal

prophylaxis for neutropenic patients. Clin Infect Dis. 2000;30:300–305.

Menichetti F et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with

hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection

Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin Infect Dis. 1999;28:250–255.

Harousseau JL et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with

hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter

trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother. 2000;44:1887–1893.

Winston DJ et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term

antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial.

Ann Intern Med. 2003;138:705–713.

Marr KA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic

stem cell transplants. Blood. 2004;103:1527–1533.

Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic

cancer patients. Bone Marrow Transplantation Team. Chemotherapy. 1994;40:136–143.

Goodman JL et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone

marrow transplantation. N EnglJ Med.1992;326:845–851.

Ellis ME et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with

haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis. 1994;13:3–

11.

Winston DJ et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a

randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495–503.

Safdar A et al. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a

comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis. 2002;44:11–16.

Cornely OA et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N EnglJ

Med. 2007;356:348–359.

Ullmann AJ et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N EnglJ Med.

2007;356:335–347.

Krishna G et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric

conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958–966.

Duarte RF et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in highrisk patients with neutropenia. Antimicrob Agents Chemother. 2014;58:5758–5765.

Gubbins PO et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant

recipients. Antimicrob Agents Chemother. 2006;50:1993–1999.

Wingard JR et al. Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of

invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood. 2007;110:55a.

Vehreschild JJ et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction

chemotherapy for acute myelogenous leukaemia (AML). J Infect. 2007;55:445–449.

Wingard JR et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive

fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–5118.

van Burik JA et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during

neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–1416.

Marr KA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasisrelated death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebocontrolled trial. Blood. 2000;96:2055–2061.

Ashbee HR et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for

Medical Mycology. J Antimicrob Chemother. 2014;69:1162–1176.

Andes D et al. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents

Chemother. 2009;53:24–34.

Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International

Antimicrobial Therapy Project Group. J Infect Dis. 1984;150:372–379.

Hughes WT et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N EnglJ Med.

1987;316:1627–1632.

Arning M et al. Infection prophylaxis in neutropenic patients with acute leukaemia—a randomized, comparative

study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin. J Antimicrob Chemother. 1990;26(Suppl D):137–

142.

Elting LS et al. Septicemia and shock syndrome due to viridans streptococci: a case-controlstudy of predisposing

factors. Clin Infect Dis. 1992;14:1201–1207.

Gafter-Gvili A et al. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance:

systematic review and meta-analysis. J Antimicrob Chemother. 2007;59:5–22.

Cullen M et al. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer. 2009;101(Suppl

1):S11–S4.

Carratala J et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with

cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20:557–560.

Horvathova Z et al. Bacteremia due to methicillin-resistant staphylococci occurs more frequently in neutropenic

patients who received antimicrobial prophylaxis and is associated with higher mortality in comparison to

methicillin-sensitive bacteriemia. Int J Antimicrob Agents. 1998;10:55–58.

Oppenheim BA et al. Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a

leukaemia unit. BMJ. 1989;299:294–297.

Gafter-Gvili A et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern

Med. 2005;142:979–995.

Oshima K et al. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic

hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical

Study Group. Transpl Infect Dis. 2010;12(5):421–427.

Takenaka K et al. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in

allogeneic hematopoietic stem cell transplant recipients. Int J Hematol. 2009;89:231–237.

Einsele H et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients

following allogeneic stem cell transplantation. Blood. 2006;107:3002–3008.

Ayala E et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic

hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:851–856.

Busca A et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell

transplantation. Transpl Infect Dis. 2007;9:102–107.

van der Heiden PL et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus

DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow

Transplant. 2006;37:693–698.

Smith TJ et al. Recommendations for the use of white blood cell growth factors: American Society of Clinical

Oncology Clinical Practice Guideline Update. J Oncol Pract. 2015;33(28):3199–3212.

National Comprehensive Cancer Network. Myeloid growth factors (version 1.2015). www.nccn.org. Accessed

September 4, 2015.

Crawford J et al. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol.

2009;20(Suppl 4):162–165.

Smith TJ et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based

clinical practice guideline. J Clin Oncol. 2006;24:3187–3205.

Oncology NCCNCPGi. Myeloid growth factors (v.1.2010).

http://wwwnccnorg/professionals/physician_gls/pdf/myeloid_growthpdf. Accessed June 21, 2010.

Bunn PA Jr et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the

treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest

Oncology Group. J Clin Oncol. 1995;13:1632–1641.

Staar S et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous

chemotherapy—results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J

Radiat Oncol Biol Phys. 2001;50:1161–1171.

Aapro M et al. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating

factors: where are we now? Support Care Cancer. 2010;18:529–541.

Seidel MG et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow

Transplant. 2008;42:679–684.

Bodey GP. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents. 2000;16:93–95.

Sickles EA et al. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–

719.

Malik I et al. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in

shock: need for better strategies. J Infect. 2001;42:120–125.

Chen SC, Kontoyiannis DP. New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and

fungal infection in febrile neutropenic patients. Curr Opin Infect Dis. 2010;23(6):567–577.

Sato M et al. Prediction of infectious events by high-sensitivity C-reactive protein level before undergoing

chemotherapy for acute myeloid leukaemia. Scand J Infect Dis. 2010;42:97–101.

Avabratha KS et al. Significance of C-reactive protein during febrile neutropenia in pediatric malignancies. Indian

Pediatr. 2009;46:797–799.

Martinez-Albarran M et al. Procalcitonin and C-reactive protein serum levels as markers of infection in a

pediatric population with febrile neutropenia and cancer. Pediatr Hematol Oncol. 2009;26:414–425.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

Sakr Y et al. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection.

2008;36:396–407.

Carnino L et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res

Clin Oncol. 2010;136:611–615.

Penack O et al. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical

management. Ann Oncol. 2008;19:984–989.

Verweij PE et al. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Moulds:

diagnosis and treatment. J Antimicrob Chemother. 2009;63(Suppl 1):i31–i35.

Girmenia C et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility

study. J Clin Oncol. 2010;28:667–674.

Maertens J et al. Preemptive antifungal therapy:still a way to go. Curr Opin Infect Dis. 2006;19:551–556.

Segal BH et al. Antibacterial prophylaxis in patients with neutropenia. J Natl Compr Canc Netw. 2007;5:235–

242.

Castagnola E et al. Clinical and laboratory features predicting a favorable outcome and allowing early discharge

in cancer patients with low-risk febrile neutropenia: a literature review. J Hematother Stem Cell Res.

2000;9:645–649.

Koh A, Pizzo PA. Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia. Cancer

Invest. 2002;20:420–433.

Vidal L et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane

Database Syst Rev. 2013;(10):CD003992.

Paganini HR et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer.

Cancer. 2000;88:2848–2852.

Freifeld A et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk

febrile patients with neutropenia during cancer chemotherapy. N EnglJ Med. 1999;341:305–311.

Kern WV et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with

granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative

Group of the European Organization for Research and Treatment of Cancer. N EnglJ Med. 1999;341:312–318.

Rolston KV et al. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support

Care Cancer. 2010;18:89–94.

Kern WV et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind,

randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus

amoxicillin/clavulanic acid combination therapy—EORTC infectious diseases group trial XV. J Clin Oncol.

2013;31:1149–1156.

Yahav D et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis.

2007;7:338–348.

Paul M et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of

randomized controlled trials. J Antimicrob Chemother. 2006;57:176–189.

Freifeld AG et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of

ceftazidime versus imipenem. J Clin Oncol. 1995;13:165–176.

Raad II et al. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic

cancer patients? Cancer. 1998;82:2449–2458.

Bow EJ et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillintazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with

hematologic malignancies. Clin Infect Dis. 2006;43:447–459.

Corapcioglu F et al. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile

neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol. 2006;23:177–186.

Ohyashiki K. Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients. Clin

Infect Dis. 2004;39(Suppl 1):S56–S58.

De Jongh CA et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer

patients. Am J Med. 1986;80:96–100.

The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long

course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

N EnglJ Med. 1987;317:1692–1698.

Furno P et al. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of

febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2002;2:231–242.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

Paul M et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with

neutropaenia. Cochrane Database Syst Rev. 2002;(2):CD003038.

Griggs JJ et al. Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile

neutropenic patients compared with standard therapy. Am J Hematol. 1998;58:293–297.

Peacock JE et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy

in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med. 2002;137:77–87.

Flaherty JP et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin

for empiric treatment of febrile neutropenic patients. Am J Med. 1989;87:278S–282S.

Chan CC et al. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for

empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother. 1989;33:87–91.

Paul M et al. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic

patients with cancer. Cochrane Database Syst Rev. 2014;(1):CD003914.

Shenep JL et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the

empirical treatment of febrile, neutropenic children with cancer. [comment]. N Engl J Med. 1988;319:1053–

1058.

Karp JE et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized,

double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med. 1986;81:237–242.

Kramer BS et al. Randomized comparison between two ceftazidime-containing regimens and cephalothingentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother. 1986;30:64–

68.

Dompeling EC et al. Early identification of neutropenic patients at risk of grampositive bacteraemia and the

impact of empirical administration of vancomycin. Eur J Cancer. 1996;32A:1332–1339.

Koya R et al. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after

autologous peripheral blood stem cell transplants. Bone Marrow Transplant. 1998;21:923–926.

Granowetter L et al. Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as the

initial therapy of the febrile neutropenic pediatric cancer patient. Pediatr Infect Dis J. 1988;7:165–170.

Paul M et al. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane

Database Syst Rev. 2005;(3):CD003914.

Shenep JL. Viridans-group streptococcal infections in immunocompromised hosts. [Review] [92 refs]. Int J

Antimicrob Agents. 2000;14:129–135.

Kennedy HF et al. Antimicrobial susceptibility of blood culture isolates of viridans streptococci: relationship to a

change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother. 2001;47:693–696.

Rybak MJ et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed

nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549–1555.

Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized

patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34:670–676.

Dilworth TJ et al. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against

clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S. aureus isolates in

vitro. Antimicrob Agents Chemother. 2014;58:1028–1033.

Moenster RP et al. Acute renal failure associated with vancomycin and beta-lactams for the treatment of

osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect.

2014;20:O384–O389.

Jaksic B et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of

febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597–607.

Chaftari AM et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related

bloodstream infections in cancer patients. Int J Antimicrob Agents. 2010;36:182–186.

Rolston KV et al. Daptomycin use in neutropenic patients with documented gram-positive infections. Support

Care Cancer. 2014;22:7–14.

Rimawi RH et al. Ceftaroline—a cause for neutropenia. J Clin Pharm Ther. 2013;38:330–332.

Varada NL et al. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with

clindamycin. Pharmacotherapy. 2015;35:608–612.

Yam FK, Kwan BK. A case of profound neutropenia and agranulocytosis associated with off-label use of

ceftaroline. Am J Health Syst Pharm. 2014;71:1457–1461.

Dalle JH et al. Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with

cancer. J Pediatr Hematol Oncol. 2002;24:714–716.

150.

151.

152.

153.

154.

155.

156.

157.

158.

159.

160.

161.

162.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

175.

Egerer G et al. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after highdose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents. 2000;15:119–123.

Marshall E et al. Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients.

Support Care Cancer. 2000;8:198–202.

Feher C et al. Effect of meropenem administration in extended infusion on the clinical outcome of febrile

neutropenia: a retrospective observationalstudy. J Antimicrob Chemother. 2014;69:2556–2562.

Krivoy N et al. Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised

pediatric patients. Infection. 1998;26:396–398.

Tod M et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely

neutropenic adults. Antimicrob Agents Chemother. 1998;42:849–856.

MacGowan AP et al. The pharmacokinetics of once daily gentamicin in neutropenic adults with haematological

malignancy. J Antimicrob Chemother. 1994;34:809–812.

Peterson AK, Duffull SB. Population analysis of once-daily dosing of gentamicin in patients with neutropenia.

Aust N Z J Med. 1998;28:311–315.

Mavros MN et al. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a

systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:251–259.

Pizzo PA et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med.

1979;67:194–200.

American Thoracic Society et al. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.

Wade JC, Glasmacher A. Vancomycin does not benefit persistently febrile neutropenic people with cancer.

Cancer Treat Rev. 2004;30:119–126.

Pappas PG et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious

Diseases Society of America. Clin Infect Dis. 2009;48:503–535.

Maertens J et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic

patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–

1250.

Prentice HG et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment

of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711–718.

Walsh TJ et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.

National Institute of Allergy and Infectious Diseases Mycoses Study Group. N EnglJ Med. 1999;340:764–771.

Wingard JR et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B

versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC

Collaborative Study Group. Clin Infect Dis. 2000;31:1155–1163.

Walsh TJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in

patients with neutropenia and persistent fever. N EnglJ Med. 2002;346:225–234.

White MH et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B

in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296–302.

Eriksson U et al. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised

controlled trial. BMJ. 2001;322:579–582.

Malik IA et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in

cancer patients with prolonged fever and neutropenia. Am J Med. 1998;105:478–483.

Winston DJ et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal

therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282–289.

Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis.

2015;61(10):1555–1565.

Walsh TJ et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with

persistent fever and neutropenia. N EnglJ Med. 2004;351:1391–1402.

Maertens JA et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin

B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J.

2010;29:415–420.

Fassas AB et al. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation:

high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol. 2001;112:237–241.

Illerhaus G et al. Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte

transfusions. Ann Hematol. 2002;81:273–281.

p. 1570

Acute retroviralsyndrome is characterized by nonspecific symptoms,

such as fever, lymphadenopathy, rash, fatigue, and night sweats that

coincide with an initial burst of viremia. These symptoms, as well as the

presence of an opportunistic infection, and high-risk sexual or drug-using

behaviors, warrant human immunodeficiency virus (HIV) testing. With

current antigen/antibody laboratory tests, HIV can be diagnosed as

early as 2 weeks after infection. In patients in whom very early

infection (<2 weeks) is suspected, nucleic acid tests for HIV RNA may

be considered for diagnostic purposes.

Case 76-1 (Question 1)

HIV RNA viral load is measured to quantify the level of viral replication

in the body and CD4 cell counts are followed to assess immune system

function.

Case 76-1 (Question 2)

Antiretroviral therapy should be offered to all patients who are willing

and able to commit to lifelong treatment after a discussion of the

benefits and risks of highly active antiretroviral therapy (HAART) and

the importance of adherence. Clinicalsituations which favor more

urgent initiation of HAART include pregnancy; AIDS-defining condition

such as an opportunistic infection; CD4 count of <200 cells/μL; HIVassociated nephropathy (HIVAN); hepatitis B and/or C infection;

rapidly declining CD4 count (>100 cells/μL decrease per year); higher

baseline viral load (>100,000 copies/mL); and acute/early HIV infection.

US Department of Health and Human Services (DHHS) guidelines

provide recommendations for optimal antiretroviral therapy.

Case 76-1 (Question 3)

Goals of antiretroviral therapy include suppression of viral load,

preservation and strengthening of the immune system, limitation of drug

adverse events, promotion of adherence, and prevention of HIV-related

morbidity and mortality.

Case 76-1 (Question 4)

General rules of therapy involve selection of HAART-based regimen,

optimization of the selected agents, and inclusion of quality of life in

decisions.

Case 76-1 (Questions 5, 6)

After initiating a HAART regimen, short-term goals include resolution of

symptoms, at least a threefold (0.5 log) decrease in HIV RNA at 1

month, a tenfold decrease (1.0 log) in HIV RNA at 2 months, and an

increase in CD4 count at 3 to 4 months. Long-term assessments include

Case 76-1 (Questions 7, 8)

the monitoring of HIV RNA and CD4 count every 3 to 6 months to

identify treatment failures, assessment of medication adherence, and

determination of tolerability and quality of life.

General rules for changing failing regimens include switching to at least

two new active drugs (although all new drugs are preferable), as quickly

as possible after treatment failure to avoid accumulation of resistance

mutations. To avoid the development of further resistance, a single drug

should never be added to a failing regimen. If one drug must be

discontinued, the whole regimen should be stopped simultaneously.

Finally, previously failed regimens should never be restarted because of

the potential of archived resistance mutations.

Case 76-1 (Questions 9, 10)

p. 1571

p. 1572